|
Description: The treatment of collected blood for transfusion in the battlefield has been identified by the Army Medical Research Acquisition Activity division of the Department of Defense as a priority for the armed forces. Naviagant Biotechnologies has been developing a process using riboflavin and light to reduce the concentrations of pathogens in collected blood components. To date, processes have been developed for treating platelets and plasma, and preliminary work has been undertaken for treating red blood cells. The purpose of this program is to evaluate the efficacy of the technology to inactivate parasites that could be a risk to the military and civilian blood supplies.
|
|
| |
| Navigant Biotechnologies |
$1,916 |
|
For-Profit |
Lakewood,
CO
|
|
|
Citation
|
|
Source:
Appropriations Report Language - Conference
|
|
Reference:
108-622
|
|
Location:
Line 29, Page 256
|
Citation Excerpt: Transportable Pathogen Reduction & Blood Safety System
|
|
